Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 1;12:46. doi: 10.1038/s41398-022-01802-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A. Regulation of CD4 + T-cells (left), Granulocytes (middle) and Natural Killer cells (right) during the exposure phase. Thicker lines represent the mean for the remitters (blue) and non-remitters (red). The adjusted p values are reported for the effect of Time in the selected LMM (see “Methods”). B. Regulation of CD4 + T-cells, CD8 + T-cells, B-cells, Granulocytes and of the granulocytes-to-lymphocyte ratio (GLR) during the course of therapy. Cell-types proportions were directly estimated from the methylation data. The adjusted p values are reported for the effect of Time in a LMM fitted on the first and last time point of the therapy.